Skip to main content
Retour
Watch Compare

MEDICINOVA INC

Qualité des données : 100%
MNOV
Nasdaq Manufacturing Chemicals
1,49 €
▲ 0,07 € (4,93%)
Cap. Boursière: 71,37 M
Prix
1,45 €
Cap. Boursière
71,37 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Revenue declined -43,56% annually over 5 years
Negative free cash flow of -9,81 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 15,47%
Capital efficient — spends only 0,71% of revenue on capex

Croissance

Revenue Growth (5Y)
-43,56%
En dessous de la moyenne du secteur (1,82%)
Revenue (1Y)-59,03%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-26,42%
Au-dessus de la moyenne du secteur (-53,34%)
ROIC-22,96%
Net Margin-2928,78%
Op. Margin-3242,47%

Sécurité

Debt / Equity
N/A
Current Ratio9,86
Interest CoverageN/A

Valorisation

PE (TTM)
-5,95
En dessous de la moyenne du secteur (-1,47)
P/B Ratio1,62
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -6,0 -1,5
P/B 1,6 1,6
ROE % -26,4 -53,3
Net Margin % -2928,8 -41,5
Rev Growth 5Y % -43,6 1,8
D/E — 0,3

Objectif de Cours des Analystes

4 analystes
Buy
Actuel
1,49 €
+504.0%
Objectif
9,00 €
6,00 €
9,50 €
11,00 €
Prévisions
P/E Prévisionnel -3,59
BPA Prévisionnel -0,42 €
CA Est. 233 330,0

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2027 -0,42 €
-0,43 € – -0,40 €
 233 330,0 2
FY2026 -0,30 €
-0,38 € – -0,26 €
 125 000,0 3

Surprises de Résultats

Derniers 4 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q42025 -0,10 € -0,05 € +47,4%
Q32025 -0,12 € -0,06 € +50,0%
Q22025 -0,12 € -0,07 € +41,7%
Q12025 -0,14 € -0,06 € +57,1%

ETFs Holding This Stock

BRSIX BRSIX
0,14% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -59,03% Revenue Growth (3Y) -36,00%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -43,56% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 409 657,0 Net Income (TTM) -12,00 M
ROE -26,42% ROA -24,64%
Gross Margin N/A Operating Margin -3242,47%
Net Margin -2928,78% Free Cash Flow (TTM) -9,81 M
ROIC -22,96% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 9,86
Interest Coverage N/A Asset Turnover 0,01
Working Capital 29,59 M Tangible Book Value 34,36 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -5,95 Forward P/E N/A
P/B Ratio 1,62 P/S Ratio 174,22
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -13,75%
Market Cap 71,37 M Enterprise Value 38,81 M
Per Share
EPS (Diluted TTM) -0,24 Revenue / Share 0,01
FCF / Share -0,20 OCF / Share -0,20
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,71% FCF Conversion 81,79%
SBC-Adj. FCF -10,68 M Growth Momentum -15,47

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 409 657,0 1,00 M 1,00 M 4,04 M 4,04 M
Net Income -12,00 M -11,05 M -8,57 M -14,07 M -10,13 M
EPS (Diluted) -0,24 -0,23 -0,17 -0,29 —
Gross Profit — — — — —
Operating Income -13,28 M -12,68 M -9,90 M -14,63 M -10,22 M
EBITDA — — — — —
R&D Expenses 6,70 M 6,80 M 5,30 M 8,70 M 8,10 M
SG&A Expenses — — — — —
D&A 20 099,0 21 077,0 20 295,0 17 707,0 26 149,0
Interest Expense — — — — —
Income Tax 5 994,0 5 537,0 3 047,0 2 822,0 2 568,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 45,60 M 55,88 M 66,27 M 74,15 M 87,41 M
Total Liabilities 4,02 M 3,37 M 3,89 M 3,91 M 3,73 M
Shareholders' Equity 41,59 M 52,50 M 62,38 M 70,24 M 83,68 M
Total Debt — — — — —
Cash & Equivalents 30,81 M 40,36 M 51,00 M 18,51 M 71,43 M
Current Assets 30,99 M 41,07 M 51,17 M 58,99 M 72,01 M
Current Liabilities 3,80 M 2,96 M 3,28 M 3,19 M 2,83 M